<DOC>
	<DOCNO>NCT00998439</DOCNO>
	<brief_summary>The aim study assess efficacy Paclitaxel-eluting PTCA - balloon catheter SeQuent® Please treat in-stent restenoses ( ISR ) various drug elute stent native coronary artery reference diameter 2.5 mm ≤ 3.5 mm lesion length ≤ 22 mm . The vessel patency follow treatment SeQuent® Please document ISR patient treat Cypher® Taxus® drug elute stent .</brief_summary>
	<brief_title>Treatment Drug-eluting Stent ( DES ) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty ( PTCA ) Catheter</brief_title>
	<detailed_description>Background information Current treatment In Stent Restenosis ( ISR ) 'uncoated balloon ' angioplasty conventional balloon ( POBA ) , Bare Metal Stent ( BMS ) implantation , cut balloon , rotablation atherectomy . Their respective result low target vessel revascularizations part unsatisfactory often conflict . Also temporary use brachytherapy lead late lumen loss ( LLL ) finding range 0.22 ± 0.84 mm . Therefore , brachytherapy treat ISR also abandon associate delayed endothelialization lead late thrombosis . The use drug elute stent ( DES ) treat ISR lower restenosis rate single digit range . Recently , use matrix coat paclitaxel-eluting PTCA balloon catheter ( SeQuent® Please , Paccocath Technology® , Bayer/Schering &amp; B.Braun Melsungen AG ) compare PES PEPCAD II trial show significantly low 6-month LLL , 6-month MACE TVR rate SeQuent® Please ( 7.25 % ) compare PES 12-month TVR rate 19.0 % therefore agreement prior study ( ISAR DESIRE ) . Since assessment do patient BMS in-stent restenosis , paramount interest study in-stent restenosis fail DES implantation since may cause continue chronic inflammatory response cause non-bioabsorbable polymer particular drug release cease .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient Related Patients stable angina pectoris ( CCS class 13 ) unstable angina pectoris ( Braunwald class 12 , AC ) document ischemia document silent ischemia Patients eligible coronary revascularization mean PCI Patients suitable coronary revascularization sort ( balloon angioplasty , deviceassisted balloonangioplasty , coronary artery bypass graft ) Patients must ≥ 18 year age Women childbearing potential may pregnant desire become pregnant first year follow study procedure . Hence , patient advise use adequate birth control method include 6 month followup Patients mentally linguistically able understand aim study show sufficient compliance follow study protocol Patients must agree undergo 6 month angiographic followup Patients must agree undergo 1 3 year clinical followup Patient able verbally acknowledge understand associate risk , benefit , treatment alternative therapeutic option trial , e.g. , balloon angioplasty mean paclitaxeleluting PTCAballoon catheter suitable device . The patient , provide informed consent , agree risk benefit state patient inform consent document . Lesion Related Instent restenosis Mehran type III stenoses reach ≤ 2 mm adjacent native vessel drug elute stent ( DES ) , native coronary artery ( reference vessel ≥ 2.5 ≤ 3.5 mm , lesion length ≤ 22 mm angiographically document ) Diameter stenosis pre procedure must either ≥ 70 % ≥ 50 % ischemia correspond target lesion document either exercise stress ECG , stress echocardiography , scintigraphy , MRT , suspect base angina pectoris . DES instent restenosis independent number metal layer ( e.g . restenosed DES follow BMS and/or DES implantation ( ) ) Patient Related Patients acute ( &lt; 24 h ) recent ( 48 hour ) myocardial infarction Patients unstable angina pectoris ( Braunwald class 3 ) Patients severe congestive heart failure Patients severe heart failure NYHA IV Patients demonstrate clinical sign cardiogenic shock time procedure ( systolic blood pressure le 80 mmHg require inotropic support , IABP and/or fluid challenge ) Patients severe valvular heart disease Women pregnant lactating patient life expectancy less five year factor make clinical followup difficult Patients another coronary stent previously implant target vessel Patients bleed diathesis anticoagulation antiplatelet medication contraindicate Patients cerebral stroke &lt; 6 month prior procedure Patient participate clinical trial involve investigational device drug Untreated hyperthyroidism Patient presence history severe renal failure ( GFR &lt; 30ml/min ) therefore eligible angiography . Patient 's serum creatinine level must document . Post transplantation organ immune suppressive medication Other disease jeopardize followup ( e.g . malignoma ) Addiction drug alcohol Patients type surgery week precede interventional procedure Conditions prevent intake double antiplatelet therapy three month Lesion Related Evidence extensive thrombosis within target vessel intervention Side branch &gt; 2 mm diameter originate stent Bifurcate lesion Left main coronary artery stenosis Multilesion percutaneous coronary intervention within artery ( main artery e.g. , LCX side branch e.g . OMS consider different artery ) Percutaneous coronary intervention venous graft Coronary artery occlusion type ( e.g . acute chronic ) Insegment stenosis native vessel within 5 mm adjacent stent Lesion within 1 mm vessel origin Related Concomitant Medication Patient intolerant aspirin and/or ADPantagonists clopidogrel history neutropenia , thrombocytopenia induced ADPantagonists , severe hepatic dysfunction prohibit use clopidogrel Patient leucopoenia ( leukocyte count &lt; 109/liter 3 day ) Patient neutropenia ( ANC &lt; 1000 neutrophils/mm3 3 day ) Patient history peptic ulcer gastric/intestinal bleeding past 6 month Patient history thrombocytopenia ( &lt; 100,000 platelets/mm3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stent restenosis</keyword>
	<keyword>paclitaxel coat balloon catheter</keyword>
	<keyword>pepcad</keyword>
	<keyword>drug elute balloon</keyword>
</DOC>